Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
PainChek. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
PainChek's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PainChek has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare PainChek's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare PainChek's earnings growth to the Australia market average as no estimate data is available.
Unable to compare PainChek's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if PainChek is high growth as no earnings estimate data is available.
Unable to determine if PainChek is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
PainChek's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Philip Daffas, BSc, Dip EENG, MBA, GAICD, has been Managing Director at PainChek Ltd. since September 30, 2016 and has been its Director since September 30, 2016. Mr. Daffas served as Vice President of Global Marketing and Sales at Pelikan Technologies, Inc. He served as Vice President of Marketing at Cochlear Limited.
Philip's compensation has been consistent with company performance over the past year, both up more than 20%.
Philip's remuneration is about average for companies of similar size in Australia.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the PainChek management team is about average.
MD & Director
CFO & Company Secretary
Chief Technology Officer
Chief Scientific Officer
Head of Business Development ANZ
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the PainChek board of directors is less than 3 years, this suggests a new board.
Board of Directors
MD & Director
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month individual insider trading information.
Imagine Owning PainChek (ASX:PCK) While The Price Tanked 58%
So it seems shareholders are too busy dreaming about the progress to come than dwelling on the current (lack of) revenue. … It seems likely some shareholders believe that PainChek will significantly advance the business plan before too long. … There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders.
PainChek Ltd. (ASX:PCK): Time For A Financial Health Check
(ASX:PCK), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is PCK growing fast enough to value financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.
What Kind Of Shareholders Own PainChek Ltd. (ASX:PCK)?
The big shareholder groups in PainChek Ltd. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of AU$34m, PainChek is a small cap stock, so it might not be well known by many institutional investors.
Is PainChek Ltd's (ASX:PCK) Balance Sheet Strong Enough To Weather A Storm?
The direct benefit for PainChek Ltd (ASX:PCK), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is PCK right in choosing financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital
Before You Invest In PainChek Ltd (ASX:PCK), Consider This
Looking at PainChek’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … The measure of how fast PainChek goes through its cash reserves over time is called the cash burn rate. … My cash burn analysis suggests that PainChek has a cash runway of 1.4 years, given its current level of cash holdings.
Why PainChek Ltd's (ASX:PCK) Ownership Structure Is Important
View our latest analysis for PainChek ASX:PCK Ownership_summary Apr 6th 18 Institutional Ownership Institutional investors are one of the largest group of market participants and their buy-sell decisions on a company's stock can significantly impact prices, more so, when there are relatively small amounts of shares available on the market to trade. … Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.
Does PainChek Ltd's (ASX:PCK) Past Performance Indicate A Weaker Future?
For the purpose of this commentary, I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … ASX:PCK Income Statement Mar 9th 18 We can further assess PainChek's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years PainChek's top-line has grown by 98.00% on average, signalling that the company is in a high-growth period with expenses racing ahead revenues, leading to annual losses.
What You Must Know About PainChek Ltd's (ASX:PCK) Financial Health
Zero-debt allows substantial financial flexibility, especially for small-cap companies like PainChek Ltd (ASX:PCK), as the company does not have to adhere to strict debt covenants. … Check out our latest analysis for PainChek Is financial flexibility worth the lower cost of capital? … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.
PainChek Ltd. provides pain assessment solutions primarily in Australia and Europe. The company offers PainChek, a smartphones pain assessment and monitoring device that automatically detects pain through facial recognition technology. It serves pre-verbal children and patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Ltd. in January 2018. PainChek Ltd. is based in Sydney, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.